The Abiologics platform leverages cutting-edge generative AI and high throughput chemical protein synthesis to create Synteins™, a new class of programmable medicines that aims to redefine what therapeutics can achieve for patients The company emerges after 3 years of platform development and an initial commitment of $50 million from Flagship PioneeringCAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Abiologics, a company reimagining biologics with the creation of a new class of supranatural and programmable medicines, called Synteins™.

非生物技术平台利用尖端的生成人工智能和高通量化学蛋白质合成来创建Synteins™，这是一类新的可编程药物，旨在重新定义该公司经过3年的平台开发和旗舰先驱Cambridge，Mass。，2024年7月23日/PRNewswire/--旗舰先驱，生物平台创新公司，最初承诺5000万美元，今天推出了非生物技术，这是一家重新设计生物制剂的公司，创建了一类新的超天然和可编程药物，称为Synteins™。

Synteins are computationally-generated and synthesized with novel building blocks, endowing them with extraordinary properties to bring life-changing treatments to patients across a wide range of diseases. Flagship has initially committed $50 million to advance the company's platform and develop a diverse pipeline of medicines, with an initial focus on oncology and immunology indications..

合成蛋白是通过计算生成的，并用新颖的构建模块合成，赋予它们非凡的特性，为各种疾病的患者带来改变生活的治疗。旗舰公司最初承诺投入5000万美元来推进公司的平台并开发多样化的药物管道，最初的重点是肿瘤学和免疫学适应症。。

Continue Reading

继续阅读

Abiologics

生物学

'Biologics have transformed medicine in the past forty years, but only a fraction of their potential has been realized because we've been limited by the boundaries of nature,' said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Chairman of the Strategic Oversight Board of Abiologics.

“生物制剂在过去四十年中改变了医学，但只有一小部分潜力得到了实现，因为我们受到自然边界的限制，”旗舰先锋创始人兼首席执行官、非生物战略监督委员会联合创始人兼主席努巴·阿费扬博士说。

'With the convergence of advancements in generative artificial intelligence, automated polymer synthesis and chemical functionalization coupled with a vision to develop more powerful medicines with unprecedented diversity, we asked, what if we could design biologics entirely from new building blocks that could overcome the most critical limitations of today's medicines?'.

“随着生成人工智能，自动化聚合物合成和化学功能化的进步以及开发具有前所未有多样性的更强大药物的愿景的融合，我们问道，如果我们可以完全从新的构建模块中设计生物制剂，以克服当今药物最关键的局限性，会怎么样？”。

The Abiologics platform is a fully integrated digital and automated wet-lab infrastructure to create supranatural biologics with powerful, desirable pharmacological properties. The platform leverages state-of-the-art generative artificial intelligence (AI) to computationally-design Synteins de novo using a broad set of artificial building blocks, far beyond the 20 naturally occurring amino acids that form the basis of today's biologic medicines.

非生物平台是一个完全集成的数字和自动化湿实验室基础设施，可创建具有强大，理想药理特性的超天然生物制剂。该平台利用最先进的生成人工智能（AI），使用广泛的人工构建块从头计算设计合成蛋白，远远超过构成当今生物药物基础的20种天然氨基酸。

These include biologics built with D-amino acids, chemically identical mirror images of standard amino acids. Once designed, Abiologics chemically synthesizes its digitally-optimized Synteins with pioneering new technologies. As a result, Synteins can be programmed to interact with virtually any therapeutic target while evading the body's natural defenses. By surpassing the limitations of traditional biologics discovery tools, Abiologics is the first to discover, prototype and scale-up polymers composed solely of artificial building blocks, and to date has successfully generated Synteins made entirely of D-amino acids that bind a diversity of therapeutically relevant targets while remaining ultrastable..

这些包括用D-氨基酸构建的生物制剂，化学上与标准氨基酸相同的镜像。一旦设计完成，Abiologics就会通过开创性的新技术化学合成其数字优化的合成蛋白。因此，合成蛋白可以编程与几乎任何治疗目标相互作用，同时逃避身体的自然防御。。。

'For the first time, we are able to imagine and generate chemically synthesized biologics at scale and with increasing programmability, offering a new class of medicines with transformative potential,' said Avak Kahvejian, Ph.D., Co-Founder and CEO of Abiologics and General Partner at Flagship Pioneering.

“这是我们第一次能够大规模想象和生产化学合成的生物制剂，并且具有越来越高的可编程性，从而提供一类具有变革潜力的新型药物，”旗舰创业公司（Flagship Exporting）非生物学联合创始人兼首席执行官阿瓦克·卡维健（Avak Kahvejian）博士说。

'Creating protein biologics with artificial building blocks rather than naturally occurring amino acids allows Synteins to go unrecognized by the immune system, offering significant advantages compared to today's biologics such as less frequent dosing, oral delivery and the ability to reach parts of the body that were previously impossible to access and treat.

“用人工构建块而不是天然存在的氨基酸制造蛋白质生物制剂，可以使合成蛋白不被免疫系统识别，与当今的生物制剂相比，具有显着的优势，例如不太频繁的给药，口服给药以及能够到达身体以前不可能进入和治疗的部位。

With Synteins, Abiologics is poised to bring boundary-breaking medicines to patients across a range of diseases.'In addition to Afeyan and Kahvejian, Abiologics' founding team includes Mike Hamill, Ph.D., Chief Innovation Officer of Abiologics and Senior Principal at Flagship Pioneering, Kala Subramanian, Ph.D., Founding President of Abiologics and Operating Partner at Flagship Pioneering, Jaclyn Dunphy, Ph.D., Senior Director of Strategy and Research Operations at Abiologics, and Alicia Kaestli, Ph.D., Senior Associate at Flagship Pioneering.

有了Synteins，Abiologics准备为各种疾病的患者带来突破边界的药物。”除了Afeyan和Kahvejian之外，Abiologics的创始团队还包括：Mike Hamill博士，Abiologics首席创新官兼Flagship Expanding高级校长；Kala Subramanian博士，Abiologics创始总裁兼Flagship Expanding运营合伙人；Jaclyn Dunphy博士，Abiologics战略与研究运营高级总监；Alicia Kaestli博士，Flagship Expanding高级助理。

Bradley Pentelute, Ph.D., Professor of Chemistry at MIT, is an Academic Co-Founder of Abiologics.About AbiologicsAbiologics is pioneering a new class of supranatural and programmable biologics, called Synteins™. The Abiologics platform leverages cutting-edge generative artificial intelligence and high-throughput chemical protein synthesis to create Synteins with powerful, desirable pharmacological properties, redefining what therapeutics can achieve for patients across a range of disease areas.

麻省理工学院化学教授BradleyPentelute博士是非生物学的学术联合创始人。关于AbiologicsAbiologics开创了一类新的超天然和可编程生物制剂，称为Synteins™。Abiologics平台利用尖端的生成人工智能和高通量化学蛋白质合成来创建具有强大，理想药理学特性的合成蛋白，重新定义了在一系列疾病领域可以为患者实现的治疗方法。

Abiologics was founded by Flagship Pioneering in 2021. For more information, vis.

Abiologics于2021年由Flagship Expandative创立。有关更多信息，请访问vis。